Powell, E. et al. Identification and characterization of a novel estrogenic ligand actinopolymorphol A. Biochem. Pharmacol. 80, 1221-1229

McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53706, USA.
Biochemical pharmacology (Impact Factor: 5.01). 10/2010; 80(8):1221-9. DOI: 10.1016/j.bcp.2010.06.030
Source: PubMed


Xenoestrogenic compounds are abundant in the modern environment including phytoestrogens from plants, chemical by-products from industry, and secondary metabolites from microbes; all can profoundly affect human health. Consequently mechanism-based screens are urgently needed to improve the rate at which the xenoestrogens are discovered. Estrogen Receptor (ER) dimerization is required for target gene transcription. The three ER dimer pairs (ERalpha/alpha homodimers, ERbeta/beta homodimers, and ERalpha/beta heterodimers) exhibit diverse physiological responses in response to ligand-dependent activation with ERalpha/alpha homodimers being pro-proliferative and ERbeta/beta homodimers being anti-proliferative. The biological role of the ERalpha/beta heterodimer remains unclear. We previously developed a cell-based, bioluminescence resonance energy transfer (BRET) assay that can distinguish natural estrogenic compounds based on their abilities to activate the three diverse ER dimer pairs. Using BRET assays, we sought to identify novel xenoestrogens from soil bacteria that preferentially activate ERalpha/beta heterodimer with hopes of shedding light on the biological function of this elusive dimer pair. Here we describe the application of BRET assays in high throughput screens of crude bacterial extracts not previously screened for ER modulatory function and originating from unique ecological niches. Here we report the discovery and biological evaluation of a new natural product, actinopolymorphol A (1), that preferentially induces ERalpha/beta dimerization. Actinopolymorphol A represents the first representative of a new ER modulatory scaffold.

Download full-text


Available from: Sheng-Xiong Huang,
  • Source
    • "Liquiritigenin selectively induced formation of ERβ/β homodimers and ERα/β heterodimers but not ERα/α homodimers at 1 µM [34], which provides proof-of-principle that small molecule compounds which preferentially induce ERα/β heterodimers over ERα/α homodimers do indeed exist. We had further shown that BRET assays can be optimized for HTS [35]. The goal of secondary HTS BRET screening in this study was to find a compound with similar characteristics to liquiritigenin but with greater ERα/β heterodimer selectivity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Estrogens play essential roles in the progression of mammary and prostatic diseases. The transcriptional effects of estrogens are transduced by two estrogen receptors, ERα and ERβ, which elicit opposing roles in regulating proliferation: ERα is proliferative while ERβ is anti-proliferative. Exogenous expression of ERβ in ERα-positive cancer cell lines inhibits cell proliferation in response to estrogen and reduces xenografted tumor growth in vivo, suggesting that ERβ might oppose ERα's proliferative effects via formation of ERα/β heterodimers. Despite biochemical and cellular evidence of ERα/β heterodimer formation in cells co-expressing both receptors, the biological roles of the ERα/β heterodimer remain to be elucidated. Here we report the identification of two phytoestrogens that selectively activate ERα/β heterodimers at specific concentrations using a cell-based, two-step high throughput small molecule screen for ER transcriptional activity and ER dimer selectivity. Using ERα/β heterodimer-selective ligands at defined concentrations, we demonstrate that ERα/β heterodimers are growth inhibitory in breast and prostate cells which co-express the two ER isoforms. Furthermore, using Automated Quantitative Analysis (AQUA) to examine nuclear expression of ERα and ERβ in human breast tissue microarrays, we demonstrate that ERα and ERβ are co-expressed in the same cells in breast tumors. The co-expression of ERα and ERβ in the same cells supports the possibility of ERα/β heterodimer formation at physio- and pathological conditions, further suggesting that targeting ERα/β heterodimers might be a novel therapeutic approach to the treatment of cancers which co-express ERα and ERβ.
    PLoS ONE 02/2012; 7(2):e30993. DOI:10.1371/journal.pone.0030993 · 3.23 Impact Factor
  • Source
    • "Fusarin C is structurally different from any other published estrogen receptor binding compound and represents a novel scaffold for estrogenic secondary metabolites. Recently, actinopolymorphol A, a compound which is also structurally different from known estrogenic compounds, was isolated from an actinomycete and identified as an estrogenic ligand (Powell et al., 2010). Thus, estrogen receptors can be activated by compounds which are structurally very different from estrogen, which emphasizes the necessity for applying biological assays to determine whether a compound has estrogenic effects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fusarin C is a mycotoxin produced by several Fusarium species and has been associated with esophageal cancer due to its carcinogenic effects. Here, we report that fusarin C stimulates growth of the breast cancer cell line MCF-7. This suggests that fusarin C can act as an estrogenic agonist and should be classified as a mycoestrogen. MCF-7 cells were stimulated in the range between 0.1 and 20μM and inhibited when the concentration exceeded 50μM. The toxicity of fusarin C is comparable to other mycoestrogens such as zearalenone, but the chemical structure of fusarin C is very different from other known estrogen agonists. Furthermore, the toxicity of fusarin C was tested in five additional human cell lines Caco 2, U266, PC3, MDA-MB-231 and MCF-10a which were all inhibited when the concentration of fusarin C exceeded 10μM. To the best of our knowledge this is the first report on the mycoestrogenic properties of fusarin C.
    Toxicology Letters 06/2011; 205(2):116-21. DOI:10.1016/j.toxlet.2011.05.1029 · 3.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Estrogen receptor ERalpha and ERbeta heterodimerization has been implicated in cancer chemoprevention. The discovery, structural elucidation, and total synthesis of a new natural product, actinopolymorphol A (1), from Actinopolymorpha rutilus (YIM45725) that preferentially induces ERalpha/beta heterodimerization is reported. Total synthesis of 1 has allowed us to determine its absolute stereochemistry and that of a previously known deacetylated congener, and 1 represents the first member of a new class of natural products not previously recognized to modulate ER function.
    Organic Letters 08/2010; 12(15):3525-7. DOI:10.1021/ol1013526 · 6.36 Impact Factor
Show more